July 15, 2016
Elanco Canada has recently received approval from Health Canada for the expanded respiratory disease treatment coverage of Pulmotil® AC.
Pulmotil® AC label claim now includes swine respiratory disease associated with Haemophilus parasuis (Glassers disease). It is also indicated as an aid in reducing the severity of swine respiratory disease (SRD) associated with Mycoplasma hyopneumoniae in the presence of the Porcine Reproductive and Respiratory Syndrome Virus (PRRSv).
Pulmotil® AC, licensed in Canada since October 2012, is a water soluble antibiotic used for the reduction in severity of swine respiratory disease associated with Actinobacillus pleurpneumoniae and Pasteurella multiocida. The product is administered in Canada solely under the direction of a veterinary prescription. Full label information is available in the Compendium of Veterinary Products.
A 2015 efficacy trial compared lung lesions in pigs co-infected with Mycoplasma hyopneumoniae and PRRS virus. Results showed a 26% reduction in lung lesions in pigs treated with Pulmotil® AC at the label dosage during the infection period. A second efficacy trial showed a significant improvement in recovery rate of pigs treated with Pulmotil® AC at the label dosage in the presence of naturally occurring infection with Pasteurella multocida and Haemophilus parasuis.
"Elanco Canada is pleased to announce these additional indications to our Pulmotil® AC label. These new indications support our veterinary customer with effective and convenient product solutions for the control of respiratory diseases," said Amber Swidersky, Elanco Canada's swine sales manager.
Dr. Randy Bagg, Elanco Canada's director of regulatory affairs and research, commented: "We continue to invest in existing products, as well as, new innovations to ensure we provide our customers with solutions within the Canadian Regulatory System for responsible antibiotic usage."